Jiangsu Vcare's Oral Treatment VC005 for Atopic Dermatitis enters Phase III Clinical Study
Published Time:
2024-10-22 17:33
Source:
VC005 tablets, developed by Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare), is a new-generation highly selective JAK1 inhibitor. The oral treatment of moderate-to-severe atopic dermatitis has initiated a Phase III clinical trial. It is a multicenter, randomized, double-blind, placebo parallel-controlled Phase III clinical study, aiming to evaluate the efficacy and safety of VC005 tablets for adult patients with moderate-to-severe atopic dermatitis. The trial is led by the Institute of Dermatology, Chinese Academy of Medical Sciences.
Positive top-line data has been obtained from the unblinded Phase II clinical study, showing key indicators, that are superior to the best drugs of the same class. Meanwhile, the overall safety and tolerability of the drug are good. In particular, adverse reactions related to the blood system in the high-dose group are milder than those of other drugs the same class, and no bone marrow suppression effect is observed.
In addition, VC005 is also being developed as a topical gel for patients with mild-to-moderate atopic dermatitis. The Phase II clinical trial is about to be initiated, and the project plans to expand its indications for atopic dermatitis in the future.
Related News
27
2017
/
03
Vice Chairman of Political Consultative Conference of Wenzhou Ouhai District Visited Jiangsu Vcare
The delegation of Political Consultative Conference of Wenzhou Ouhai District, accompanied by vice chairman of Political Consultative Conference of Pukou Economic Development Zone visited Jiangsu Vcare Pharmaceutical Technology Co., Ltd. on the afternoon of March 27, 2017. Yongqiang Liu, the general manager of Jiangsu Vcare received the delegation. Mr. Liu introduced the company's development history and R&D progress. He focused on the progress of phase II clinical trials and the future market prospect of innovative drug Vicagrel. The delegation highly recognized Vcare's advanced equipment and facilities, harmonious human environment and comprehensive research and development capabilities.
View Details
14
2017
/
03
Jiangsu Vcare Held “Firefighting and First Aid” Training
Jiangsu Vcare invited Lei Wang, a special instructor of Nanjing Anqu Fire Education Center to give a “Firefighting and First Aid” course to new employees on March 14, 2017 and 26 new employees participated in the training. Mr. Wang collected a large number of fire cases and carefully analyzed the causes of these fires. He taught everyone how to deal with fires. His explanations made everyone fully aware of the importance and urgency of fire safety. At the same time, everyone had a better understanding of various fire extinguishers and their instructions.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn